A Single-site Postmarket Retrospective Chart Review of Subdermal Coagulation Procedures with Renuvion

Although tumescent liposuction provides debulking of body areas with excess subcutaneous fat and concurrent skin laxity, the ability to shrink and redrape the skin and soft tissue for added definition has remained an elusive goal. Many modalities employed to facilitate fat removal utilizing light energy, ultrasonic energy, or radiofrequency energy have provided modest skin shrinkage. Apyx Medical’s (formerly Bovie Medical) Renuvion (previously branded as J-Plasma) has Food and Drug Administration clearance for the cutting, coagulation, and ablation of soft tissue. The objective of this retrospective chart review was to collect safety and procedural information for patients who have previously undergone liposuction with which Renuvion was used as a tool for subdermal coagulation. All procedures occurred before August 2018. Thirty-two patients were identified (3 male and 29 female). The mean follow-up was 6 months (range, 3–8 months). None of the patients required a revision or secondary procedure suggesting 100% of patients had acceptable final outcomes. No device-related adverse events or complications were noted, suggesting that within this data set, Renuvion’s unique cool helium plasma technology can safely be used for skin contraction with or without tumescent liposuction or supplemental modalities used to facilitate fat removal that may otherwise contribute to the skin contraction.